GLP-1 (Glucagon-Like Peptide-1 (7-36) amide) is a synthetic 30-amino acid peptide hormone analog derived from the proglucagon sequence.

It was characterized in the 1980s through foundational research by Dr. Svetlana Mojsov, Dr. Joel Habener, and collaborators at Massachusetts General Hospital, building on earlier proglucagon gene work. No single company founded the native peptide; it originated from academic and institutional research.

Researchers have investigated GLP-1 in preclinical and early clinical models for its role in stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing food intake. 

Studies have explored its potential applications in metabolic regulation, type 2 diabetes models, body weight management, and related endocrine and cardiovascular research.